Results 181 to 190 of about 30,063 (226)
Journal of Biological Chemistry, 2010 InhA, the primary target for the first line anti-tuberculosis drug isoniazid, is a key enzyme of the fatty-acid synthase II system involved in mycolic acid biosynthesis in Mycobacterium tuberculosis.
Sathya Narayanan Nagarajan +2 more
exaly +2 more sources
First Triclosan-Based Macrocyclic Inhibitors of InhA Enzyme
Bioorganic Chemistry, 2020 Two macrocyclic derivatives based on the triclosan frame were designed and synthesized as inhibitors of Mycobacterium tuberculosis InhA enzyme. One of the two molecules M02 displayed promising inhibitory activity against InhA enzyme with an IC50 of 4.7 μM.
Christian Lherbet +2 more
exaly +6 more sources
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Journal of Biomolecular Structure and Dynamics, 2016
The closed conformation of substrate binding loop (SBL) is considered significant for biological activity of direct InhA inhibitors (DIIs). However, exact interactions of SBL with inhibitors are not characterized yet to emphasize over SBL conformations.
Masilamani Elizabeth Sobhia
exaly +3 more sources
The closed conformation of substrate binding loop (SBL) is considered significant for biological activity of direct InhA inhibitors (DIIs). However, exact interactions of SBL with inhibitors are not characterized yet to emphasize over SBL conformations.
Masilamani Elizabeth Sobhia
exaly +3 more sources
Novel Compounds Targeting InhA for TB Therapy
Pharmacological Reports, 2018Tuberculosis (TB) is described as lethal disease in the world. Resistant to TB drugs is the main reason to have unfavourable outcomes in the treatment of TB. Therefore, new agents to replace existing drugs are urgently needed. Previous reports suggested that InhA inhibitors, an enoyl-ACP-reductase, might provide auspicious candidates which can be ...
Essam A Makky, Isil Var, Fatih Koksal
exaly +3 more sources
European Journal of Medicinal Chemistry, 2012 A series of triazoles have been prepared and evaluated as inhibitors of InhA as well as inhibitors of Mycobacterium tuberculosis H(37)R(v). Several of these new compounds possess a good activity against InhA, particularly compounds 17 and 18 for which ...
Christian Lherbet +2 more
exaly +2 more sources
A new ‘golden age’ for the antitubercular target InhA
Drug Discovery Today, 2017The increasing prevalence of multidrug-resistant strains of Mycobacterium tuberculosis is the main contributing factor in unfavorable outcomes in the treatment of tuberculosis. Studies suggest that direct inhibitors of InhA, an enoyl-ACP-reductase, might yield promising clinical candidates that can be developed into new antitubercular drugs.
Kaja Rožman +6 more
openaire +2 more sources
Klinische Erfahrungen mit INHA-PAS
Beiträge zur Klinik der Tuberkulose und spezifischen Tuberkulose-Forschung, 1956Es wird uber klinische Erfahrungen an 54 Fallen mit INHA-PAS behandelter Lungentuberkulose berichtet. Das Praparat wird der Kombination INH und PAS mindestens gleichgestellt, was den therapeutischen Effekt angeht. Es wird die Uberlegenheit des Praparates in Hinsicht auf Vertraglichkeit, Dosierbarkeit und Wirtschaftlichkeit betont.
openaire +1 more source